KR101165716B1 - Compositions for prevention and treatment of allergic disease comprising the fractions from the extracts of Gardenia jasminoides as an active ingredient - Google Patents

Abstract

The present invention Gardenia The present invention relates to a composition for the prevention or treatment of allergic diseases containing a fraction of jasminoides extract as an active ingredient. Specifically, the gardenia fraction fractionated from the gardenia extract lowers the amount of histamine released from mast cells and is allergic. Since it reduces dermatitis and ear edema and reduces serum IgE concentration in the sex atopic dermatitis disease model, it can be usefully used for the prevention, amelioration or treatment of allergic diseases.

Description

Compositions for prevention and treatment of allergic disease comprising the fractions from the extracts of Gardenia jasminoides as an active ingredient}

The present invention relates to a composition for the prevention or treatment of allergic diseases containing a plant fraction as an active ingredient.

Allergies are known to have a hypersensitive response to allergens, which are harmless antigens due to innate or acquired abnormalities in immune function. The allergic reaction is mediated by IgE, one of the types of antibodies, the immune response mechanism is as follows. Once our body is exposed to allergens, allergens are recognized by circulating antigen presenting cells that differentiate Th0 (T helper0) into Th2 cells by presenting allergens. These differentiated Th2 cells secrete cytokines such as IL-4, IL-5 and IL-13, which promote the development of acidic white blood cells in bone marrow to induce acidic white blood cells into inflamed tissues, Acts to induce the production of IgE and IgG1. IgE produced through this mechanism of action strongly binds to mast cells through the IgE receptor called FcεRI in tissues. Later exposure to the same allergen, when allergen binds to IgE bound to mast cells, the mast cells secrete histamine, prostaglandins, heparin, proteases and free radicals, which cause various allergic symptoms and persist Induce chronic inflammation of the tissue (Galli SJ et al ., 2008, Nature 454 (7203), 445-454).

Allergic diseases include anaphylaxis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, Hives, pruritus, insect allergies, food allergies or drug allergies.

Representative allergic agents currently commonly used include antihistamine, steroidal or nonsteroidal anti-inflammatory drugs. However, they are mainly known to have a symptomatic effect, and are not known to cure the root cause of allergy that alleviates excessive humoral immunity or inhibits IgE production. Therefore, there is no need for drugs that can treat the root cause of allergies without side effects.

Gardenia is Rubiaceae (Rubiaceae) Plants of gardenia (Gardenia jasminoides ) [KP IX, 2007]. Gardenia is known to be used as an anti-inflammatory, diuretic, or hemostatic agent, or to treat jaundice. It is used to dye cloth or radish yellow, and to dye the whole yellow to yellow, using candle or ash as a mordant.

Therefore, the present inventors are trying to develop a natural substance having a prophylactic or therapeutic effect of an allergic disease, the fraction of the gardenia extract inhibits the release of histamine, edema, dermatitis and blood IgE of the atopic dermatitis disease mouse model The present invention was completed by confirming that the effect of reducing the concentration is remarkable compared to that of the extract of Gardenia jasminoides, which can be usefully used as an active ingredient for the prevention and treatment of allergic diseases.

The object of the present invention is Gardenia It is to provide a pharmaceutical composition for the prevention or treatment of allergic diseases containing a fraction of jasminoides ) extract as an active ingredient, and a cosmetic or health food for improving allergic diseases.

In order to achieve the above object, the present invention is Gardenia It provides a pharmaceutical composition for the prevention or treatment of allergic diseases containing a fraction of the jasminoides ) extract as an active ingredient.

The present invention also provides a cosmetic composition for the prevention and improvement of allergic diseases containing a fraction of the gardenia extract as an active ingredient.

In addition, the present invention provides a health food for the prevention and improvement of allergic diseases containing a fraction of the gardenia extract as an active ingredient.

Gardenia of the present invention Fractions isolated from jasminoides ) extracts lower the histamine secretion in mast cells, reduce dermatitis and ear edema in atopic dermatitis disease models, and reduce serum IgE levels, thus preventing allergic diseases or It can be usefully used as an active ingredient of a therapeutic composition.

1 is Gardenia Figure shows the preparation of fractions of jasminoides ) extract.
Figure 2 is a graph showing the inhibitory effect of histamine secretion of Gardenia fraction and Gardenia extract.
3 is a graph showing the dermatitis reducing effect of the gardenia fraction.
Figure 4 is a graph showing the atopic dermatitis inhibitory effect of the gardenia fraction.
5 is a graph showing the effect of reducing the serum IgE concentration of the gardenia fraction.

Hereinafter, the present invention will be described in detail.

The present invention Gardenia It provides a composition for the prevention or treatment of allergic diseases containing a fraction of the jasminoides ) extract as an active ingredient.

The allergic disease may include anaphylaxis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, It is preferably, but not limited to, a pharmaceutical composition for the prevention or treatment of allergic diseases, characterized in that it is any one selected from the group consisting of urticaria, pruritus, insect allergy, food allergy and drug allergy disease.

Fractions of the gardenia extract is preferably prepared by a manufacturing method including the following steps, but not always limited thereto.

1) extracting by adding an extraction solvent to the gardenia;

2) cooling the extract of step 1) and filtering; And

3) drying the filtered extract of step 2) under reduced pressure and then drying; And

4) Step 3) preparing a fraction by adding the organic solvent to the dry extract

In the above method, the gardenia of step 1) can be used without limitation, such as grown or commercially available.

The extraction solvent is preferably water, alcohol or a mixture thereof. As the alcohol, C ₁ to C ₄ lower alcohols are preferably used, and as the lower alcohols, ethanol or methanol is preferably used, but is not limited thereto. As the extraction method, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction may be used, and the extraction may be preferably performed one to five times by the hot water extraction method, and more preferably, two times extraction is not limited thereto. . The extraction solvent is preferably extracted by adding 5 to 15 times to the weight of dried gardenia, and more preferably by adding 10 times. The extraction temperature is preferably 40 to 80 ° C and more preferably 50 to 60 ° C, but is not limited thereto. In addition, the extraction time is preferably 1 to 5 hours, more preferably 2 hours is not limited thereto.

In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration in step 3), but it is not limited thereto. In addition, drying may be used under reduced pressure drying, vacuum drying, boiling drying, spray drying or lyophilization, preferably lyophilization, but is not limited thereto.

In the above method, the organic solvent of step 4) is preferably hexane (n-hexane), dichloromethane (dichloromethane) and ethyl acetate (ethyl acetate), more preferably ethyl acetate, but is not limited thereto. Do not.

In the above method, the fraction of step 4) is a 70% ethanol extract suspended in distilled water and mixed the same amount of hexane (n-hexane) and then put into a separatory funnel to separate and remove the hexane layer, the same amount in the remaining water layer After dichloromethane was mixed, the dichloromethane layer was separated, and then, the remaining amount of water was mixed with the same amount of ethyl acetate, and the ethyl acetate layer was separated, concentrated and freeze-dried. It is preferred to prepare fractions.

The fraction may be obtained by repeating the fractionation process from the gardenia extract 1 to 5 times, preferably 3 times, preferably concentrated under reduced pressure after the fraction, but is not limited thereto.

In a specific embodiment of the invention, the gardenia was washed with water and then dried in the shade and at room temperature. The dried gardenia was placed in an extraction container, and extracted with the extraction solvent at 50 ~ 60 ℃ for 2 hours and filtered through a filter paper. The extract was concentrated under reduced pressure at 50 ~ 55 ℃ and lyophilized to prepare a gardenia extract.

Fraction of the gardenia extract is preferably prepared by a manufacturing method comprising the step of preparing a fraction by adding an organic solvent in addition to the gardenia extract prepared as described above, but is not limited thereto.

 In a specific embodiment of the present invention, the present inventors measured the amount of allergic histamine production in mouse mast cells in order to investigate the inhibitory effect of allergic histamine of the gardenia extract and fraction of the present invention. As a result, it was confirmed that the gardenia fraction inhibits the secretion of allergic histamine in a concentration-dependent manner, and by confirming the inhibitory effect of allergic histamine in comparison with the gardenia extract, it has an excellent allergic histamine inhibitory effect than the gardenia extract See figure 2).

In order to examine the anti-allergic effect in allergic atopic dermatitis disease, the present inventors confirmed the anti-allergic effect of gardenia extract and gardenia fraction in allergic atopic dermatitis induced mouse model. As a result, it was confirmed that the Gardenia fraction significantly reduced dermatitis and the Gardenia fraction significantly reduced ear edema compared to the extract of Gardenia (see FIGS. 3 and 4). In addition, as a result of measuring the total IgE concentration in blood serum of allergic atopic dermatitis mice after the end of the experiment, the total IgE concentration was significantly reduced compared to the case where the gardenia extract was treated in the gardenia fraction (see FIG. 5).

Therefore, the inhibition of inflammation-induced histamine secretion of the fraction isolated from the gardenia extract of the present invention and the anti-allergic effect by the allergic atopic dermatitis disease model were confirmed, and the fraction of the gardenia extract as an organic solvent was used for preventing or treating allergic diseases. It can be usefully used as an active ingredient of the pharmaceutical composition.

The composition of the present invention is preferably a pharmaceutical composition, and in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. Can be used.

The subject to which the composition according to the invention can be applied is a vertebrate and preferably a mammal, more preferably an experimental animal such as a rat, rabbit, guinea pig, hamster, dog, cat, most preferably a chimpanzee or gorilla Such are ape-like animals.

In addition, the compositions of the present invention may be administered orally or parenterally, but parenteral administration (eg, application or intravenous, subcutaneous, intraperitoneal injection) is preferred, and application is more preferred.

Solid form preparations for oral administration include powders, granules, tablets, capsules, soft capsules, and the like. Oral liquid preparations include suspensions, solvents, emulsions, syrups, and aerosols.In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Formulations for parenteral administration may include powders, granules, tablets, capsules, sterile aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, syrups, suppositories, aerosols, and the like, in accordance with conventional methods. It can be formulated and used in the form of injectables, and preferably, an external skin pharmaceutical composition of cream, gel, patch, spray, ointment, warning, lotion, linen, pasta or cataplasma is prepared. Can be used, but is not limited thereto. Compositions of topical administration may be anhydrous or aqueous, depending on the clinical prescription. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

In order to effectively treat allergic dermatitis, it is important to select a suitable external preparation. In order to treat allergic dermatitis, the gardenia fraction of the present invention may be appropriately diluted and applied directly to the skin, and the pharmaceutical composition for treating allergy of the present invention may be prepared as an ointment so that it can be effectively applied to the affected area. The ointment is prepared by combining the pharmaceutical composition for treating allergies of the present invention with an inorganic substance and then coating it with a fat-soluble base. The inorganic material is preferably used a material having excellent antibacterial, anti-inflammatory effect, epidermal regeneration effect, and specific examples thereof include zinc oxide, zinc carbonate, iron oxide. In addition, it is preferable to further use a ceramic carrier that can safely impregnate the pharmaceutical composition for treating allergies of the present invention, which is a water-soluble substance. As the ceramic carrier, zeolite, talc, gypsum, seed powder and mixtures thereof are preferably used. Such a ceramic carrier is excellent in the impregnation of the water-soluble component can facilitate the supply of the water-soluble component to the skin.

The pharmaceutical composition may be prepared by including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredient for administration. Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, as antioxidants, buffers And other conventional additives such as bacteriostatic agents can be added. In addition, diluents, dispersants, surfactants, binders and lubricants may be additionally added to formulate injectable formulations such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it may be preferably formulated according to each disease or component by an appropriate method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.

The composition according to the present invention may further comprise conventionally used excipients, disintegrants, sweeteners, lubricants, flavoring agents and the like. The disintegrants include sodium starch glycolate, crospovidone, croscarmellose sodium, alginic acid, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, chitosan, guar gum, low-substituted hydroxypropyl cellulose, magnesium aluminum silicate, and polyacryline Potassium and the like. In addition, the pharmaceutical composition according to the present invention may further include a pharmaceutically acceptable additive, wherein the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, Calcium hydrogen phosphate, lactose, mannitol, malt, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, opadry, sodium starch glycolate, carnauba lead, synthetic aluminum silicate, stearic acid, magnesium stearate, Aluminum stearate, calcium stearate, sucrose, dextrose, sorbitol, talc and the like can be used. The pharmaceutically acceptable additive according to the present invention is preferably included 0.1 to 90 parts by weight based on the pharmaceutical composition.

The dosage of the composition of the present invention varies depending on the body weight, age, sex, health condition, diet, time of administration, method of administration, excretion rate and severity of the disease, and the daily dosage is separated from the gardenia extract. It is 0.0001 to 100 mg / kg, preferably 0.001 to 10 mg / kg, based on the amount of fraction, and may be administered 1 to 6 times a day.

The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers.

In addition, the present invention provides a cosmetic composition for the prevention and improvement of allergic diseases containing a fraction of the gardenia extract with an organic solvent as an active ingredient.

 The allergic disease is any one selected from the group consisting of hypersensitivity, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria, pruritus, insect allergy, food allergy and drug allergy disease It is preferred that the cosmetic composition for the prevention and improvement of allergic diseases, characterized in that but not limited thereto.

Therefore, the anti-allergic effect was confirmed by inhibiting the inflammation-induced histamine secretion of the fraction isolated from the gardenia extract of the present invention and allergic atopic dermatitis disease model, thereby confirming the anti-allergic effect. One fraction may be usefully used as an active ingredient of the cosmetic composition for the prevention and improvement of allergic diseases.

The cosmetic composition may be in the form of a solution, a gel, a solid or a paste anhydrous product, an emulsion obtained by dispersing an oil phase in water, a suspension, a microemulsion, a microcapsule, a microgranule or an ionic (liposome) A cream, a skin, a lotion, a powder, an ointment, a spray, or a cone stick. It may also be prepared in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.

In addition, the cosmetic composition, in addition to the gardenia fraction of the present invention, in addition to fatty substances, organic solvents, solubilizers, thickening and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, Commonly used in water, ionic or nonionic emulsifiers, fillers, metal ion sequestrants and chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or cosmetics And any other ingredients that may be used, such as auxiliaries commonly used in the cosmetic field.

In addition, the present invention provides a health food for the prevention and improvement of allergic diseases containing a fraction of the gardenia extract with an organic solvent as an active ingredient.

The allergic disease is any one selected from the group consisting of hypersensitivity, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria, pruritus, insect allergy, food allergy and drug allergy disease It is preferable that the health food for prevention and improvement of allergic diseases, characterized in that but not limited thereto.

Therefore, the anti-allergic effect was confirmed by inhibiting the inflammation-induced histamine secretion of the fraction isolated from the gardenia extract of the present invention and allergic atopic dermatitis disease model, thereby confirming the anti-allergic effect. One fraction may be usefully used as an active ingredient in health foods for the prevention and improvement of allergic diseases.

The gardenia fraction of the present invention may be added as it is or used with other food or food ingredients, and may be appropriately used according to conventional methods.

There is no particular limitation on the kind of the food. Examples of foods to which the gardenia fraction may be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionary, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, teas, and drinks. Alcoholic beverages and vitamin complexes, and includes all of the health foods in the conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The proportion of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.

In addition to the above, the gardenia fraction of the present invention is various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage. In addition, the gardenia fraction of the present invention may contain pulp for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, the present invention will be described in detail by way of examples, comparative examples and production examples.

However, the following Examples, Comparative Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples, Comparative Examples and Preparation Examples.

< Comparative example  1> Preparation of Gardenia Extract

300 g of Gardenia jasminoides purchased from OmniHub (Daegu, Korea) was dried and pulverized, and then immersed in 70% aqueous ethanol solution (70% EtOH) corresponding to 10 times the sample weight and stirred. Thereafter, the mixture was extracted twice under reflux for 2 hours at an extraction temperature of 50 to 60 ° C. and filtered through a filter paper. The extract was concentrated under reduced pressure using a concentrator at 50-55 ° C., and then freeze-dried to give 70% ethanol extract (73.2 g).

< Example  1> Gardenia extract Fraction  Produce

The 70% ethanol extract obtained in <Comparative Example 1> was suspended with distilled water, and then, the same amount of hexane (n-hexane) was mixed and then separated into a separatory funnel to separate and remove the hexane layer. Dichloromethane was mixed with the remaining water layer in the same amount, and then the dichloromethane layer was separated and removed. Ethyl acetate (ethyl acetate) was added to the remaining water layer, followed by fractionation. The ethyl acetate layer was separated, concentrated and freeze-dried to prepare an ethyl acetate fraction (FIG. 1).

< Experimental Example  1> By mast cell model Anti-allergy  Experiment

<1-1> Cell Culture

MC / 9 cells, mouse mast cells, were purchased from the American Type Culture Collection (ATCC, USA) to obtain 10% heat-inactivated Fetal Bovine Serum (FBS), 100 units / ml penicillin (penicillin), 100 μg / ml Streptomycin (dreptomycin) added in DMEM medium was incubated in 37 ° C, 5% CO ₂ environment.

<1-2> Inflammatory histamine ( histamine Secretion measurement

Cultured MC / 9 mouse mast cells were inoculated into 96-well plates and then 25 ug / ml of compound 48/80 and 0, 100, 200, 400 and 800 μg / ml of Gardenia extract or 0, by known methods. Gardenia fractions of 50, 100, 200 and 400 μg / ml were treated for 20 minutes (Bytautiene et al ., 2008, Int Aech Allergy Immunol 147, 140-146; Kim EK et al ., 2007, Biosci Biotechnol Biochem 71, 2886-2892). Thereafter, the amount of allergic histamine secreted in the medium was measured by ELISA kit (Oxford Biomedical Research Inc., USA). 100% activity of histamine inhibition was calculated as the difference in histamine secretion between groups treated with compound 48/80 not treated (Equation 1).

Compound 48/80 (25 μg / ml) and samples were treated with mouse MC / 9 mast cells at different concentrations (0, 25, 50, 100, 200, 400 μg / ml) and incubated for 20 minutes. The production of secreted allergic histamine was measured in a microreader (please describe the manufacturer) using the ELISA kit (Oxford Biomedical Research Inc., USA). The 100% production of histamine was defined as the compound 48/80 million treated group to calculate the relative production (% control) of the sample treated group. All measurements were expressed as mean and standard deviation (SD), and the differences between the experimental groups were statistically analyzed using Student's t-test, and statistically significant when p <0.05. It was determined that.

As a result, gardenia extract, or it was confirmed that the fraction is dependently inhibited the release of allergic histamine concentration, gardenia extract inhibited histamine release potency IC ₅₀ of = 400.44 μg / ml, and the inhibitory effect of the gardenia fraction was IC ₅₀ It was confirmed that the value = 126.33 μg / ml Gardenia fraction showed an excellent histamine inhibitory effect compared to the extract (3.16 times). This confirmed the excellent inhibitory effect on allergic histamine of the gardenia fraction (Fig. 2).

< Experimental Example  2> Allergic  In Atopic Dermatitis Disease Models Anti-allergy  Efficacy Experiment

<2-1> experimental animals and breeding conditions

5.5-week-old male NC / Nga mouse (Oshio et al .) Is widely used as an allergic atopic dermatitis model. al ., 2009, International Immunopharmacology 9, 403-411) was supplied from a central laboratory animal, and the environment was controlled at a temperature of 20-22 ° C, a relative humidity of 40-60%, and a 12-hour interval. Purified to adapt. Feed and drinking water were freely ingested and 6 animals were randomly distributed for each group.

<2-2> Allergic  Atopic Dermatitis Animal Model Making

Allergic atopic dermatitis was caused by application of an allergic atopic dermatitis ( Dermathophagoides farinae extract, Biostir-AD, Astellas, Japan) to skin of 8-week-old NC / Nga mice (Oshio et. al ., 2009). On the day before the experiment, both ears and back hairs of the mice were removed using a hair remover (JD-S-138, THRIVE, Japan) and a hair removal cream (veet, Reckitt benckiser, France). Only the epilator was used for the subsequent antigen application. . 150 μl of 4% sodium dodecyl sulfate (SDS) was applied on the day of the experiment (Day 0), and left for 2-3 hours. D. farinae antigen was applied to the back (100 mg / mouse) and both ears (10 mg / mouse). Each was applied. SDS and antigen application were performed twice a week, six times for three weeks.

<2-3> Allergic  Gardenia Extract and Gardenia in Atopic Dermatitis Animals Fraction  process

To determine the anti-allergic efficacy of extracts and fractions, 30 minutes before the atopic dermatitis was induced in the allergic atopic dermatitis mice of Experimental Example <2-2>, acetone: Gardenia extract (400 μg) dissolved in distilled water (3: 1) / Mouse) or gardenia fractions (200 μl / mouse) were applied to the back and ears of the experimental group and applied daily for about two weeks from day 7 of antigen application.

<2-4> Allergic  Gardenia extract and in atopic dermatitis animals Fraction  Dermatitis suppression confirmation

As in Experimental Example <2-3>, the degree of skin damage was assessed twice a week in allergic atopic dermatitis mice treated with Gardenia extract or fraction. Erythema / hemorrhage, edema, abrasion / erosion, scarring / dryness are divided into three levels (0; none, 1; mild, 2; moderate). , 3; severe) was evaluated by a known method (Yamamoto M et. al ., 2008, Arch Dermatol Res ahead of print ).

As a result, the extracts of Gardenia jasminoides and fractions all reduced the dermatitis compared with the disease group. Especially, the Gardenia jasminoides fraction was approximately twice as much as the dermatitis reduction level of the extract of Gardenia jasminoides at 1/2 dose of the extract from the 14th day after the start of the experiment. It was confirmed to make (Fig. 3).

<2-5> Allergic  Gardenia extract and in atopic dermatitis animals Fraction  Ear edema changes

In mice treated as in Experimental Example <2-3>, the thickness of each ear was measured twice a week with a dial thickness gauge (M110-25, Mitutoyo, Japan) to calculate an increase rate as an allergic edema index. 100% edema rate was defined as the group treated with antigen alone to give a relative edema rate (% of control). All measurements were expressed as mean and standard deviation (SD), and the differences between the experimental groups were statistically analyzed using Student's t-test and statistically significant when p <0.05. It was determined that.

As a result, ear thickness of normal and antigen-treated diseased mice was 0.36 mm and 0.75 mm, respectively, and when treated with gardenia extract, the ear thickness was 0.60 mm, showing 64.02% ear edema rate. In the case of 0.52 mm, the edema rate of 40.11% was shown that half the dose of the extract was more effective in inhibiting ear edema than the extract ( P <0.05). As a result, it was possible to confirm the atopic dermatitis inhibitory effect of the extract of Gardenia jasminoides or the fraction, in particular anti-allergic activity through the excellent edema inhibitory effect of the gardenia fraction (Fig. 4).

<2-6> Allergic  Gardenia extract and in atopic dermatitis animals Fraction  serum IgE  Confirmation of concentration reduction effect

In the mice treated as in Experimental Example 2-3, blood was collected after the end of the experiment, and the total IgE concentration in serum was measured in a microreader using a mouse IgE ELISA kit (Shibayagi Co, Japan).

As a result, the treatment of the gardenia extract or fractions showed that the serum IgE concentration was decreased, especially in the gardenia fraction (59%), which was significantly reduced compared to the treatment (77%). Even if the amount was used, it was confirmed that the gardenia fraction has a high serum IgE inhibitory effect (FIG. 5).

< Manufacturing example  1> Preparation of Pharmaceutical Formulations

<1-1> Sanje  Produce

2 g of gardenia fraction of the present invention

Lactose 1 g

The above components were mixed and packed in airtight bags to prepare powders.

<1-2> Preparation of Tablet

100 mg of Gardenia fraction of the present invention

Corn starch 100 mg

100 mg of milk

2 mg of magnesium stearate

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

&Lt; 1-3 > Preparation of capsules

100 mg of Gardenia fraction of the present invention

Corn starch 100 mg

100 mg of milk

2 mg of magnesium stearate

After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.

&Lt; 1-4 >

1 g of gardenia fraction of the present invention

Lactose 1.5 g

1 g of glycerin

Xylitol 0.5 g

After mixing the above components, it was prepared to be 4 g per ring according to a conventional method.

<1-5> Preparation of granules

Gardenia fraction of the present invention 150 mg

Soybean extract 50 mg

200 mg of glucose

600 mg of starch

After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 ° C. to form granules, which were then filled into fabrics.

< Manufacturing example  2> manufacture of cosmetics

As cosmetics containing the gardenia fraction of the present invention as an active ingredient, cosmetics of an emulsified formulation such as nutrient cosmetics, creams and essences, and cosmetics of solubilized formulations such as softening cosmetics were prepared.

<2-1> Cosmetic Preparation of Emulsion Formulation

Cosmetics of the emulsifier type were prepared with the composition shown in Table 1. The manufacturing method is as follows.

1) The mixture which mixed the raw materials of 1-9 was heated at 65-70 degreeC.

2) 10 was added to the mixture of step 1).

3) The mixture of the raw materials of 11-13 was heated at 65-70 degreeC, and was completely dissolved.

4) While passing through step 3), the mixture of 2) was slowly added to emulsify for 2 to 3 minutes at 8,000 rpm.

5) The raw material of 14 was dissolved in a small amount of water, and then added to the mixture of step 4) and emulsified for 2 minutes.

6) 15 to 17 of the raw materials were weighed, respectively, and added to the mixture of step 5) and emulsified for 30 seconds.

7) After emulsifying the mixture of step 6) through a degassing process to prepare a cosmetic of emulsion type by cooling to 25 ~ 35 ℃.

Composition of Emulsifying Formulations 1, 2, 3 Furtherance Emulsifier 1 Emulsifier 2 Emulsifier 3 One Stearic acid 0.3 0.3 0.3 2 Stealy alcohol 0.2 0.2 0.2 3 Glyceryl Monostearate 1.2 1.2 1.2 4 Wax 0.4 0.4 0.4 5 Polyoxyethylene sorbitan
Monolauric acid ester 2.2 2.2 2.2 6 Methyl paraoxybenzoate 0.1 0.1 0.1 7 P-hydroxybenzoic acid profile 0.05 0.05 0.05 8 Cetylethylhexanoate 5 5 5 9 Triglyceride 2 2 2 10 Cyclomethicone 3 3 3 11 Distilled water To 100 To 100 To 100 12 Concentrated glycerin 5 5 5 13 Triethanolamine 0.15 0.15 0.15 14 Polyacrylic acid polymer 0.12 0.12 0.12 15 Pigment 0.0001 0.0001 0.0001 16 incense 0.10 0.10 0.10 17 Gardenia fraction of the present invention 0.0001 One 10

<2-2> Solubilization  Cosmetic preparation of the formulation

A cosmetic of solubilized formulation was prepared with the composition shown in Table 2. The manufacturing method is as follows.

1) Raw materials 2 to 6 were placed in raw material 1 (purified water) and dissolved using a still mixer.

2) The raw materials of 8 to 11 were put into the raw material of 7 (alcohol) and completely dissolved.

3) The mixture of step 2) was solubilized with slow addition to the mixture of step 1).

Solubilization  Composition of Formulations 1, 2, 3 Furtherance Solubilized Formulation 1 Solubilized Formulation 2 Solubilized Formulation 3 One Purified water To 100 To 100 To 100 2 Concentrated glycerin 3 3 3 3 1,3-butylene glycol 2 2 2 4 EDTA-2Na 0.01 0.01 0.01 5 Pigment 0.0001 0.0002 0.0002 6 Gardenia fraction of the present invention 0.1 5 5 7 Alcohol (95%) 8 8 8 8 Methyl paraoxybenzoate 0.1 0.1 0.1 9 Polyoxyethylene
Hydrogenated Ester 0.3 0.3 0.3 10 incense 0.15 0.15 0.15 11 Cyclomethicone - - 0.2

< Manufacturing example  3> Manufacture of food

Foods containing the gardenia fraction of the present invention were prepared as follows.

<3-1> Production of flour food

0.5-5.0 parts by weight of the gardenia fraction of the present invention was added to the flour, and bread, cake, cookies, crackers and noodles were prepared using this mixture.

<3-2> soup  And juicy ( gravies Manufacturing

0.1 to 5.0 parts by weight of the gardenia fraction of the present invention was added to soups and broths to prepare meat products for health promotion, soups and noodles of noodles.

<3-3> Ground Beef  Produce

10 parts by weight of the gardenia fraction of the present invention was added to the ground beef to prepare a ground beef for health promotion.

<3-4> Dairy products ( dairy products Manufacturing

5 to 10 parts by weight of the gardenia fraction of the present invention was added to milk, and various milk products such as butter and ice cream were prepared using the milk.

<3-5> Solar  Produce

Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.

Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.

The gardenia fraction of the present invention was concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by drying with a spray and a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.

The grains, seeds and the ethyl acetate fractions of <Example 1> prepared above were prepared by combining the following ratios:

Cereals (30 parts by weight brown rice, 15 parts by weight brittle, 20 parts by weight of barley),

Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)

Ethyl acetate fraction of Example 1 (3 parts by weight),

Ganoderma lucidum (0.5 parts by weight), and

Sulfur (0.5 part by weight).

< Manufacturing example  4> Manufacturing of beverages

<4-1> Health drink  Produce

Instant sterilization was carried out by homogeneously combining 5 g of the gardenia fraction of the present invention with a subsidiary material such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%) and water (75%). Then it was prepared by packaging in a small packaging container such as glass bottles, plastic bottles.

<4-2> Production of vegetable juice

5 g of the gardenia fraction of the present invention was added to 1,000 ml of tomato or carrot juice to prepare vegetable juice.

<4-3> Preparation of fruit juice

1 g of the gardenia fraction of the present invention was added to 1,000 ml of apple or grape juice to prepare a fruit juice.

Claims (12)

Water, C ₁ ~ Gardenia jasminoides extract extracted with lower alcohol of C ₂ or a mixed solvent thereof was extracted from the aqueous layer of n-hexane fraction, the aqueous layer of dichloromethane, and ethyl acetate. A pharmaceutical composition for the prophylaxis or treatment of any allergic disease selected from the group consisting of allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria and pruritus.
delete delete delete Water, C ₁ ~ Gardenia jasminoides extract extracted with lower alcohol of C ₂ or a mixed solvent thereof was extracted from the aqueous layer of n-hexane fraction, the aqueous layer of dichloromethane, and ethyl acetate. Cosmetic composition for the prevention and improvement of any one allergic disease selected from the group consisting of allergic dermatitis (allergic dermatitis), atopic dermatitis, contact dermatitis, urticaria and pruritus.
delete delete delete Water, C ₁ ~ Gardenia jasminoides extract extracted with lower alcohol of C ₂ or a mixed solvent thereof was extracted from the aqueous layer of n-hexane fraction, the aqueous layer of dichloromethane, and ethyl acetate. Health food for the prevention and improvement of any one allergic disease selected from the group consisting of allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria and pruritus. delete delete delete

Images